Australia markets closed

    +125.60 (+1.82%)

    -0.0032 (-0.49%)
  • ASX 200

    +116.40 (+1.74%)
  • OIL

    -0.41 (-0.47%)
  • GOLD

    -8.30 (-0.48%)

    -66.98 (-0.21%)
  • CMC Crypto 200

    +11.20 (+2.52%)

MedX Health Applies for Extension of Price Protection for Private Placement Convertible Loan Note Financing

·2-min read

MISSISSAUGA, Ontario, August 11, 2022--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, in connection with the Private Placement (the "Financing"), the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, it has applied to the TSX Venture Exchange for an extension of a further 30 days price protection in order to complete subscriptions for up to a total of $4 million. Further Closings, will be subject to receipt of subscriptions and a number of other conditions, including, without limitation, the receipt of all relevant regulatory and Stock Exchange approvals or acceptances.

The Financing is a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000 ("Convertible Notes"), the terms of which are fully described in the Company’s Press Release dated July 14, 2022.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. For more information, visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on


Bill Mitoulas, Investor Relations
MedX Health Corp.